A multimodal dataset for precision oncology in head and neck cancer

Marion Dörrich¹, Matthias Balk², Tatjana Heusinger^{2,3}, Sandra Beyer^{2,4}, Hassan Kanso², Christian Matek⁵, Arndt Hartmann^{5,6}, Heinrich Iro², Markus Eckstein^{5,6†}, Antoniu-Oreste Gostian^{2,3,6†}, Andreas M. Kist^{1*†}

¹Department Artificial Intelligence in Biomedical Engineering, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, 91052, Germany. ²Department of Otolaryngology - Head and Neck Surgery, University Hospital Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, 91054, Germany.

³Department of Otorhinolaryngology, Head and Neck Surgery, Merciful Brothers Hospital St. Elisabeth, Straubing, 94315, Germany.

⁴Department of Oral and Maxillofacial Surgery, University Hospital Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, 91054, Germany. ⁵Institute of Pathology, University Hospital Erlangen,

Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, 91054, Germany. ⁶Comprehensive Cancer Center EMN, University Hospital Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), Erlangen, 91054,

Germany.

*Corresponding author(s). E-mail(s): andreas.kist@fau.de; †These authors contributed equally as senior authors.

Abstract

Head and neck cancer is a common disease and is associated with a poor prognosis. A promising approach to improving patient outcomes is personalized treatment, which uses information from a variety of modalities. However, only little progress has been made due to the lack of large public datasets. We present a multimodal dataset, HANCOCK, that comprises monocentric, real-world data of 763 head and neck cancer patients. Our dataset contains demographical, pathological, and blood data as well as surgery reports and histologic images. We show its potential clinical impact in a multimodal machine-learning setting by proposing adjuvant treatment for previously unidentified risk patients. We found that especially the multimodal model outperformed single-modality models (area under the curve (AUC): 0.85). We believe that HANCOCK will not only open new insights into head and neck cancer pathology but also serve as a major source for researching multimodal machine-learning methodologies in precision oncology.

1

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

1 Introduction

Head and neck cancer is the seventh most common malignancy worldwide [1]. Patients
diagnosed with head and neck cancer have a poor prognosis [2]. Despite recent
advances in diagnostics and treatments, such as immunotherapy, the 5-year survival
ranges only between 25% and 60% [3]. The most common head and neck cancer develops in several locations, e.g. the oral cavity, pharynx, or larynx, and is derived from
squamous cells, i.e. originates from the mucosal epithelium lining the inner areas of
these sites. The cancer often spreads to regional lymph nodes, which further worsens
the prognosis of affected patients [4].

After assessing the medical history and physical examination, a panendoscopy 10 with biopsy is usually performed to confirm the diagnosis. The pathological analysis 11 of tissue samples is crucial for determining the histological entity. Additionally, lymph 12 nodes are examined for possible metastases. Surgery is one of the most important 13 pillars of treatment for head and neck cancer. Local surgery is often sufficient for lower-14 stage cancer, while adjuvant treatment such as radiotherapy or radiochemotherapy is 15 required for higher stages [5]. Despite many advances in diagnostics, the treatment 16 choice still depends mainly on the stage of the disease that is mainly determined by the 17 size of the tumor [5, 6]. However, research showed that cancer is highly diverse among 18 patients [7] and therefore requires precision oncology. The key to this personalized 19 treatment is the establishment of reliable and predictive biomarkers. Initiatives such 20 as The Cancer Genome Atlas (TCGA) have already achieved a better understanding 21 of the genetic and molecular characteristics of many types of cancer [8]. 22

However, very few biomarkers are currently used in routine head and neck cancer 23 treatment. A positive prognostic biomarker is the association with human papillo-24 mavirus (HPV) in oropharyngeal carcinomas [9]. Ongoing research aims to explore if 25 their treatment can be de-escalated to reduce toxicity [10]. Furthermore, the expres-26 sion of programmed death ligand 1 (PD-L1) can be assessed to identify patients who 27 may benefit from immune checkpoint inhibitors such as pembrolizumab, and remains 28 the only applied predictive biomarker for now [11]. However, more reliable biomarkers 29 need to be established to enable a truly personalized treatment. Although information 30 from a large variety of sources is routinely acquired, its full potential cannot be real-31 ized for data-driven exploration yet. Careful data curation and multimodal integration 32 are required to unravel complex data dependencies. We hypothesize that a lack of 33 such large, multimodal, publicly available datasets hinders the research of predictive 34 biomarkers for head and neck oncology. 35

To our knowledge, existing head and neck cancer datasets only have a lim-36 ited number of cases or have inconsistent metadata [12-15]. For example, a study 37 focusing on radiomics included data from 288 cases while only selecting oropharyn-38 geal carcinomas [15]. Another dataset focusing on proteomics includes radiology and 39 histopathology data but is limited to 122 cases [13]. Comprehensive data including 40 clinical, genomic, and histopathologic data has been collected on TCGA from more 41 than 500 cases to date, however, the multicenter data is very heterogeneous [12, 16]. 42 To address these issues, we collected monocentric, retrospective data from more 43 than 700 head and neck cancer patients. We built a comprehensive dataset from multi-44 modal data including demographics, blood data, surgery reports, pathologic data, and 45

⁴⁶ histologic images. These include Whole Slide Images (WSIs) with routine hematoxylin
⁴⁷ and eosin (HE) staining and Tissue Microarrays (TMAs) with staining for several
⁴⁸ immune cell populations. In this work, we aimed to explore and provide reproducible
⁴⁹ strategies for multimodal integration and analysis. We aimed to predict patient out⁵⁰ comes and investigate adjuvant treatment choices using multimodal Machine Learning
⁵¹ (ML) strategies to show the impact of multimodal data integration for head and neck
⁵² oncology.

53 **Results**

⁵⁴ Compilation of a multimodal dataset from a head and neck ⁵⁵ cancer cohort

Patient diagnoses and treatment decisions are rarely based on a single modality; 56 hence, artificial intelligence (AI) models intended to assist clinicians should adopt a 57 holistic approach, incorporating multiple data sources. Training such models requires 58 extensive and diverse patient data, which is often scarce. To address this, we have 59 aggregated a comprehensive dataset, HANCOCK (Head And Neck Cancer dataset), 60 which consists of real-world data from 763 patients. In detail, we collected, cleaned, 61 and harmonized routinely acquired monocentric data from patients diagnosed with 62 oral cavity, oropharyngeal, hypopharyngeal, and laryngeal cancer. We integrated dif-63 ferent modalities including demographics, blood data, pathology reports, surgery 64 reports, and histologic images, as shown in Figure 1A. We provide an overview and 65 easy, public access to the individual patient data for convenient manual exploring at 66 www.hancock.research.fau.eu with support of the FAUDataCloud. 67

A core strength of HANCOCK is its rich base of imaging data: HE-stained WSIs 68 of the primary tumor are available for 701 out of 763 patients. We provide also manual 69 annotations of tumor regions in these WSIs, as shown in Supplementary Fig. S1. In 70 addition, 396 HE-stained slides of adjacent lymph nodes were included. Each patient 71 contains at most 32 TMAs, which reflect two cores, eight stains, and two locations. 72 Each core is stained with either HE or immunohistochemistry (IHC) markers, such as 73 CD3 and PD-L1. Figure 1B shows exemplarily the available imaging data for a single 74 patient. For each patient, the pathology report was included in a structured format. 75 These cover tumor characteristics such as the primary site or grading (see Figure 1E) 76 crucial for selecting a suitable treatment. Additional characteristics such as tumor 77 staging, resection margin, and infiltration depth are summarized in Supplementary 78 Fig. S2. 79

As shown in Figure 1C, 80% of the patients in the dataset are males and 72%80 are former or current smokers. The median age is 61 years. Thus, our patient cohort 81 reflects the current demographics of head and neck cancer [1], which is beneficial for 82 generalizing our findings to a broader population. The laboratory data includes the 83 84 complete blood count as well as coagulation parameters, electrolytes, renal function parameters, and C-reactive protein. Figure 1D shows for how many patients the indi-85 vidual parameters are available and how many of the measured blood parameters are 86 in the normal or abnormal range. 87



Fig. 1 Overview of the multimodal head and neck cancer dataset. (A) Data sources. For cancer diagnosis, demographics were assessed and blood tests were performed. In the ablative surgery, tissue samples were obtained and the pathological report was written. The dataset also features information about the treatment choice, events, and survival. (B) Image data of a patient. Shown are Whole Slide Images of the primary tumor and lymph node with hematoxylin and eosin (HE) staining and Tissue Microarray cores from the tumor center and invasion front with HE and immunohistochemistry (IHC) staining. (C) Demographical data, shown as the number of patients per sex, smoking status, and age at initial diagnosis. (D) Laboratory data. Shown is the number of patients for which each parameter is available. The colors indicate values inside or outside of the normal range. (E) Primary tumor site or CUP (cancer of unknown primary) and grading from the pathology report. HPV-associated carcinoma was not graded. (F) Number of words in each German surgery report grouped by pathological T stage. (G) Kaplan-Meier plot of overall survival with 95% confidence interval shown as shaded error.

The incorporation of treatment information and temporal event data allows an in-depth analysis of the underlying relationships. To this end, we extracted and de-identified plain text descriptions of the surgery and medical history from text documents. Figure 1F illustrates the length of surgery reports, which seems to increase with the pathological T stage. All German text files were translated into English to improve their accessibility (see Methods). OPS codes (German procedure classification) define

4

the medical procedures applied. We also extracted ICD codes (International Statis-94 tical Classification of Diseases and Related Health Problems) of the German version 95 ICD-10-GM from the text documents. The ICD codes allow a detailed classification 96 of malignancies and their sites. The most frequent ICD codes were C10.8 and C32.0, 97 as shown in Supplementary Fig. S3D. C10.8 corresponds to a malignant neoplasm 98 in overlapping regions of the oropharynx and C32.0 corresponds to a malignant neo-99 plasm of the glottis [17]. We believe that ICD coded will allow easy subsampling of 100 the full dataset. 101

In HANCOCK, each patient is tracked from the time of initial diagnosis to either 102 the end of follow-up or death, with follow-up periods lasting as long as 14 years (see 103 Supplementary Fig. S4). This enables the examination of temporal information, for 104 example in the form of treatment timelines (see Supplementary Fig. S5) and sur-105 vival analyses. Figure 1G shows the overall survival of all patients in the HANCOCK 106 dataset. Survival curves with additional information such as the number of censored 107 patients can be found in Supplementary Fig. S6D and survival curves grouped by pri-108 mary site, stage, and grading are shown in Supplementary Fig. S6A-C. The 5-year 109 survival rate in our cohort is 77.3%. 110

Overall, the dataset features a great variety of modalities for a large patient cohort (763 cases), which resembles the global demographics of head and neck cancer.

Multimodal data integration allows prediction of clinical outcomes

After carefully aggregating the patient data, we were next interested in investigat-115 ing the overall patient collective. To better understand the complex patient data, we 116 encoded information from each modality individually and concatenated these encod-117 ings into vectors, termed multimodal patient vectors, as shown in Figure 2A. Given 118 the high-dimensional nature of these vectors (the multimodal patient vectors con-119 tain 103 dimensions each, see Methods), these patient-centered features can hardly 120 be examined or interpreted by humans. Therefore, we applied Uniform Manifold 121 Approximation and Projection (UMAP) to these vectors to project them into a lower, 122 two-dimensional space, as shown in Figure 2B and C. In Supplementary Fig. 7, we 123 provide a comprehensive overview of incorporated features and their distribution in 124 the UMAP projection. 125

Subsequently, we sought to identify distinct patient clusters using these multi-126 modal patient vectors. We hypothesized that similar patient groups would converge 127 within specific areas of the two-dimensional UMAP projection. Our findings confirm 128 this hypothesis, as we observed that patients sharing particular characteristics tended 129 to form distinct clusters. For instance, patients diagnosed with HPV-positive oropha-130 ryngeal carcinoma often exhibited a high density of CD8+ cells, as illustrated in 131 Figure 2C. Additionally, our analysis revealed that both CD3+ and CD8+ cell den-132 sities at the tumor center and the invasion front were notably higher in patients who 133 did not experience recurrence compared to those who did (Supplementary Fig. S8). 134 These observations are consistent with prior studies in head and neck oncology [9], 135 underscoring the relevance and accuracy of the HANCOCK dataset. 136



Fig. 2 Multimodal embeddings. (A) For each patient, information from distinct modalities were encoded and concatenated to multimodal patient vectors. (B) We applied Uniform Manifold Approximation and Projection (UMAP) to visualize the vectors in 2D and we implemented a genetic algorithm to create two test datasets, one in the distribution of the training data and one out of the distribution. (C) Visualization of two-dimensional embeddings, colored by features of the encoded data. (D) UMAP plots of three different train-test splits (E) Receiver-operating characteristics (ROC) curves of a Random Forest classifier for the three splits and two prediction tasks. The mean values and standard deviations of the ROC curves and Area under the Curve (AUC) scores are shown. The colors correspond to the different splits in D.

We aimed to investigate whether ML models could predict clinical outcomes, i.e. 137 recurrence and survival status, using the encoded multimodal data. We were also 138 interested in defining different hold-out test datasets that would allow a robust esti-139 mation of a model's performance. To this end, we defined three data splits that divide 140 the cases into one training and one test set. We hypothesize that the performance of 141 models can be over- or under-estimated depending on how similar the test data is to 142 the training data, especially in a complex, high-dimensional, and multimodal setting 143 as in our case. To address and investigate this issue, we implemented a genetic algo-144 rithm to automatically define two dataset splits based on multidimensional features. 145 The algorithm uses evolutionary optimization to find (i) cases that follow the over-146 all distribution ("in distribution") or (ii) cases that lie outside the distribution and 147 are maximally dissimilar to each other ("out of distribution"). In both settings, the 148 genetic algorithm preserves the distribution of target classes (recurrence and survival 149

status) in the resulting training and test sets, which is important for model evaluation [18]. The respective class distributions are shown in Supplementary Fig. S9C-D. Additionally, we defined a third split where all patients with a carcinoma located in the oropharynx were assigned to the test dataset, rendering it very dissimilar and biased to the training data. These three training/test data splits are highlighted in the UMAP representation in Figure 2D.

Next, we trained an ML model, namely a Random Forest classifier, to predict the 156 recurrence and survival status of each patient by using the multimodal patient vectors 157 as inputs. This corresponds to an early fusion approach since the modality vectors 158 are first concatenated and then used to train a single model [19]. Figure 2E shows the 159 performance of the classifiers for the previously mentioned train-test splits (see Figure 160 2D for reference). As expected, the model had difficulty predicting patient outcomes 161 for the test dataset consisting of cases with oropharyngeal carcinoma, a primary site 162 that the model has not seen during training. This is highlighted by the lowest Area 163 Under the Curve (AUC) score as shown in Figure 2E compared to the other test sets. 164 In accordance with our hypothesis, the classification performance was higher for the 165 "in distribution" than the "out of distribution" test dataset as shown in Figure 2E. 166 Overall, we can provide evidence that multimodal ML models follow expected ML 167 behavior and were able to successfully estimate the prognosis of patients, achieving a 168 maximum average AUC score of 0.79 for both recurrence and survival prediction. 169

¹⁷⁰ Multimodal machine learning enables improved adjuvant ¹⁷¹ treatment selection

An important choice in oncologic therapy is whether an adjuvant treatment is required 172 for a given patient. That means, identifying risk patients that benefit from an adju-173 vant therapy is crucial. We analyzed the HANCOCK patient cohort and found that 174 some patients did not receive adjuvant treatment, but eventually had a recurrence or 175 deceased (Figure 3A), suggesting that exactly this patient collective are risk patients 176 who would have potentially benefited from adjuvant therapy. We assume that all other 177 patients in our dataset received appropriate treatment to the best of the treating 178 physicians' knowledge. We then were interested in how the potentially unidentified 179 risk patients would have been classified (adjuvant therapy needed yes/no) by a mul-180 timodal ML model. Hence, we assigned these cases to a hold-out test dataset (Figure 181 3A). The remaining cases, i.e. cases with adjuvant therapy and cases without adjuvant 182 therapy and no recurrence or death, were assigned to a training dataset. 183

First, we evaluated the benefits of multimodality vs. single modalities. Therefore, 184 we trained ML models on the multimodal patient vectors and each of the modalities 185 separately. These modalities include clinical, pathological, and blood data as well as 186 the density of CD3- and CD8-positive cells and ICD codes. Figure 3B shows the 187 corresponding average Receiver-operating characteristic (ROC) curves using 10-fold 188 cross-validation. As shown in Figure 3B, the classifier integrating the multimodal 189 data outperformed all single-modality classifiers with a mean AUC score of 0.85. This 190 finding is in line with previous works that have shown the superior performance of 191 ML models trained on several modalities compared to data with limited information 192 from a single source [20, 21]. Out of the single-modality models, the classifier trained 193

> on pathological data achieved the highest mean AUC score of 0.81, as shown in Figure 194 **3**B. 195

> We next trained a classifier on the full, multimodal training data. Figure 3C shows 196 the predictions of this trained model for the hold-out test dataset, i.e. the potential 197 risk patients (orange cohort in Figure 3A). Figure 3C reveals that the multimodal ML 198 classifier suggested an adjuvant therapy for 74 out of 100 cases. Furthermore, Figure 199 3D shows that the 74 patients for whom an adjuvant treatment was proposed, were 200 high-risk patients i.e. their probability of recurrence-free survival and overall survival 201 were significantly lower than for the other 26 patients ($p \leq 0.001$, log-rank test). 202

> The incorporation of ML in clinical practice is often hindered by a lack of 203 explainability and its "black box" nature [22]. To improve the interpretability of our 204 multimodal approach, we obtained SHAP values that explain the impact of individ-205 ual features on the model output [23]. Figure 3E shows the twelve most important 206 characteristics in a summary plot. The four features with the highest impact were 207 pathological features, agreeing with the high AUC score of the pathological model in 208 Figure 3B. For example, a high pathological N and T stage led to a higher probabil-209 ity of predicting an adjuvant treatment. These two features had the greatest impact 210 on the predictions, which is consistent with the fact that the treatment choice mainly 211 depends on the stage of the disease [5]. However, adjuvant treatment was not likely to 212 be predicted for laryngeal carcinomas and glottic carcinomas in particular, as shown 213 in Figure 3E as the ICD code C32.0 stands for malignant neoplasms of the glottis [17]. 214 A demographic feature, namely the age at initial diagnosis, also had a high impact 215 on the outputs; With increasing age, the need for an adjuvant therapy became less 216 likely. Furthermore, an HPV association had a high impact on not predicting adjuvant 217 treatment, which is consistent with results showing that HPV-positive patients have a 218 better prognosis [9] (see survival grouped by HPV status in Supplementary Fig. 6D). 219 Taken together, our results suggest that multimodal models can integrate more 220 valuable information than single modality models, and could be useful for assisting in 221 adjuvant treatment selection: in this case, 3 out of 4 patients would have potentially 222 benefited from an adjuvant therapy questioning current clinical guidelines and sug-223 gesting the incorporation of multimodal ML models. We showed that our ML model 224 relied on the stage and also on a variety of other characteristics such as infiltration

Treatment choice prediction using immunohistochemistry 227 images 228

depth, perinodal invasion, age, and HPV association.

225

226

Computer vision approaches on histopathological image data have shown promising 229 results in a variety of oncology settings [21, 22, 24]. We were interested if the image 230 data in the HANCOCK dataset is as well suited for multimodal data integration. 231 Using the dataset split shown in Figure 3A, we explored an approach for integrating 232 image features and the encoded tabular data to train a convolutional, deep neural 233 network. To this end, we analyzed the TMAs taken from the tumor center. Each 234 TMA contains multiple samples and two cores were available for each patient, as 235 shown in Figure 4A. We extracted a single $1024 \times 1024 \ \mu m$ tile from each TMA core. 236 Figure 4B shows that we used TMAs stained with seven distinct IHC markers and 237



Fig. 3 Prediction of treatment choice. (A) Patients who did not receive adjuvant therapy but did have a recurrence or deceased within 5 years (highlighted in orange) were assigned to the test dataset. All other patients were assigned to the training dataset. (B) Receiver-operating characteristic (ROC) curves of Random Forest classifiers trained on single-modal and multimodal data using 10-fold cross-validation with the mean Area Under the Curve (AUC). (C) The multimodal model predicted adjuvant therapy for 74% of cases in the test dataset. (D) Kaplan-Meier curves for the test dataset, with patients grouped by predictions. The log-rank test was used. (E) SHAP summary plot for model interpretability, showing the 12 most important features of the multimodal model (trained on the full training data), computed for all validation folds.

the standard HE stain. All tiles were fed to a VGG16 pre-trained on ImageNet to
extract high-level features [25, 26]. The features were "deep texture representations"
of the images, following the technique of Komura et al. [27]. We found that there was
a relationship between these image representations and the computed cell density of
CD3- and CD8-positive cells, as shown in Supplementary Fig. S10.

For each patient, a two-dimensional embedding was created by stacking the image features and the multimodal patient vectors (see Methods). The resulting image-like

embeddings were used to train a Convolutional Neural Network (CNN, see Figure 4)
to the same task as in Figure 3.

Figure 4D shows that the network achieved a mean AUC of 0.81 in 10-fold cross-247 validation. Thus, it did not outperform the ML model trained on the high-level 248 multimodal patient vectors alone (compare Figure 3C) but performed in a similar 249 range. We hypothesized that some parts of the multimodal feature vectors con-250 tained information that overlapped with the information in the image embeddings, 251 namely the structured pathological data and cell densities, which are derived from 252 the histopathological imaging data. Figure 4D shows that models lacking these fea-253 tures resulted in a decrease in the classification performance. We found that the CNN 254 was still able to reach a mean AUC of 0.69 on the image representations alone which 255 indicates that valuable information was contained in the extracted features. 256

The network predicted an adjuvant treatment for 58 out of 100 cases, see Figure 4E. The respective Kaplan-Meier curves (see Figure 4F) show that the overall and recurrence-free survival probability was significantly lower in patients, for whom the model suggested adjuvant therapy ($p \leq 0.001$ and $p \leq 0.01$, log-rank test).

Next, we were interested in analyzing the impact of different modalities on the 261 CNN's predictions. We generated SHAP image plots to create visual explanations. An 262 example is shown in Figure 4G. We found that patterns within the image embeddings 263 as well as individual features in the multimodal patient vectors were highlighted. This 264 indicates that stacking extracted image features and encoded tabular features might 265 be a valuable approach to multimodal Deep Learning with the advantage of being 266 computationally inexpensive. Overall, we were able to integrate image data using a 267 simple early fusion approach to train a deep neural network, yielding promising results. 268

269 Discussion

In this study, we provide a novel monocentric dataset - HANCOCK - comprising 763 270 patients with multimodal data. The modalities include demographical, pathological, 271 and blood data, WSIs from primary cancer and lymph nodes, and TMAs with IHC 272 staining. We show that the dataset is rich and diverse, and not biased towards a single 273 domain (Figures 1 and 2). By integrating multimodal data through diverse machine 274 and deep learning approaches, we can show that this allows better prediction of sur-275 vival and recurrence (Figure 2F), as well as providing a superior choice for adjuvant 276 therapy across AI technologies (Figures 3 and 4). With our transparent and open 277 approach, we hope the HANCOCK dataset will fuel further developments in multi-278 modal data integration and head and neck oncology. By reproducing previous findings, 279 such as the predictive behavior of HPV and PD-L1, we believe that HANCOCK will 280 be very useful in biomarker discovery and validation. 281

We found some limitations in our work, which can be addressed in future studies. For example, we did not integrate WSIs of the primary tumors or lymph nodes to train deep neural networks. Instead, we focused on TMA tiles as inputs since they provide information about distinct immune cell populations and are also available with routine HE staining. Another advantage of using the TMAs was that they were taken specifically from the tumor region. However, integrating the HE-stained WSIs



Fig. 4 Combining multimodal feature vectors with image embeddings. (A) Tile extraction. From each TMA cores (two cores per patient), a tile was extracted from the center. (B) Vgg16, pre-trained on ImageNet, was used to extract deep texture representations [27] from tiles extracted from TMAs with 8 distinct markers, of which 7 are immunohistochemistry markers. (C) Stacking of features to train a Convolutional Neural Network for treatment choice prediction. (D) Receiver-operating characteristic (ROC) curves from 10-fold cross-validation. In the left plot, all modalities were used. In the center plot, pathological features and cell densities were excluded. In the right plot, the multimodal patient vectors were excluded. (E) Predictions for the test dataset. (F) Kaplan-Meier curves for the test dataset, with patients grouped by predictions (G) Visual explanation using SHAP values for a test sample.

additionally could further improve the prediction of clinical outcomes or treatment choices since multiple studies have shown that neural networks trained on WSIs alone can predict risk or prognosis, for example using Multiple-Instance-Learning [28–30].

We further relied consistently on an early fusion approach for training any multi-291 modal AI in our study. This means first fusing the features of distinct modalities and 292 then training a single model, which is recommended as an initial strategy [19]. Future 293 studies should also evaluate if the classification performance could be improved using 294 joint fusion, where neural networks are not only used as feature extractors but are also 295 trained in the process [19]. An in-depth comparison of different methods for extracting 296 and fusing features, especially from our comprehensive histologic image data, could 297 be very beneficial. 298

> We extracted ICD codes from the surgery reports and integrated them into multimodal embeddings using bag-of-words. However, we did not incorporate the plain texts themselves. Since the surgery reports describe the tumor resection in detail and could potentially provide additional information about the severity of the disease, they could be further explored. For example, text embeddings could be extracted using a pre-trained transformer and integrated into the multimodal vectors [20].

> Our Machine Learning models are limited to binary classification, however, other options could be explored using the available event data. For example, a regression model could be implemented to predict the time to events such as recurrence or death. Moreover, models could be trained to predict risk scores using a loss function such as Cox partial likelihood loss as proposed by Chen et al. [21].

> In this work, the densities of CD3- and CD8-positive cells were computed from the TMAs. We analyzed these regarding their relationship to clinical outcomes (see Supplementary Fig. S8) and integrated them in the multimodal vectors for ML model training (see Figure 2A). In the future, immune cells expressing the markers CD56, CD163, PD-L1, and MHC-1 as available in HANCOCK could be analyzed as well and integrated for ML model training accordingly.

> A limitation of our multimodal ML model for treatment prediction is that it could not account for all possible reasons for deciding against adjuvant therapy. For example, no data about patient refusal or comorbidities was available. Hence, collecting more detailed information about the process of treatment selection could be beneficial.

> It has been shown that tissue or cell detection and subsequent classification can 320 enable the investigation of quantitative biomarkers [31, 32]. Therefore, annotations 321 of the histologic images in our dataset could be beneficial for biomarker discovery. 322 We already provide manual annotations of tumor regions in the WSIs of the primary 323 tumor. However, these annotations were done sparsely instead of exhaustively and 324 they were not done by pathologists. We aim to extend HANCOCK in the future, 325 for example by creating high-quality annotations of distinct cell types. To this end, 326 we could leverage Deep Learning models and existing manual annotations of nuclei. 327 The annotation or segmentation of larger tissue regions could also be considered and 328 incorporated into the dataset. Further, combining molecular data with histopatholog-329 ical data is a promising approach [33]. Hence, we aim to further integrate genomic or 330 transcriptomic data, to increase the long-term impact of the dataset. 331

> Finally, HANCOCK allows the possibility to explore the concept of digital twins, a digital representation of cancer patients, that could improve decisions in cancer care [34]. We implicitly used this concept in the training/test data split (Figure 2) to compute the cosine similarity between patients to ensure a specific distribution of patients in a given subset (see Methods).

337 Methods

338 Data collection

The data was acquired from the Department of Otorhinolaryngology and Head and Neck Surgery and from the Pathological Institute of the University Hospital in Erlangen. All data was collected and published following the local ethics committee vote

(#23-22-Br). Retrospective, multimodal data was gathered from patients who were
diagnosed with head and neck cancer between 2005 and 2019. Only patients who
had a curative first treatment were included. The modalities in our dataset can
be categorized into image data (histopathological images), structured data (clinical,
pathological, and blood data), and free text (surgery reports). Supplementary Fig.
S11 shows the available and missing data types for all patients.

Tissue samples of the respective patients were collected from the pathological 348 archive of the University Hospital in Erlangen. The samples originate from the pri-349 mary tumor and, if present, positive lymph nodes that had been resected. The tissue 350 samples had been fixed in formalin, embedded in paraffin, and routinely stained with 351 HE. The 709 primary tumor sections were scanned using a 3DHistech P1000 at $82.44 \times$ 352 magnification. A single slide was available for 701 cases whereas two slides were avail-353 able for eight cases. The 396 lymph node sections were scanned using an Aperio Leica 354 Biosystems GT450 at $40 \times$ magnification and using 3DHistech P1000 at $51.42 \times$ mag-355 nification. All digitized WSIs were stored in the pyramidical Aperio file format (.svs). 356 Additionally, TMAs were created from the paraffin-embedded primary tumor blocks. 357 The TMA cores with a diameter of 1.5 mm were extracted from the tumor center and 358 the tumor invasion front. They were stained using HE and they were stained for spe-359 cific immune cell populations using the IHC markers CD3, CD8, CD56, CD68, CD163, 360 PD-L1, and MHC-1. CD3-positive cells represent T cells, CD8-positive cells repre-361 sent cytotoxic T cells, and CD56-positive cells represent natural killer cells. CD68 and 362 CD163 were used to detect monocytes and macrophages. PD-L1 plays a major role in 363 regulating the immune response. It is expressed by tumor cells to deactivate cytotoxic 364 T cells and is a target for immunotherapy [35]. The major histocompatibility com-365 plex class I (MHC-1) displays antigens to cytotoxic T cells and is also important for 366 determining the prognosis and treatments involving immunotherapy [36]. From each 367 patient, at least two cores were collected per origin and marker. This resulted in 368 368 TMAs, each with cores arranged in 12 rows by 6 columns. The TMAs were scanned 369 using a 3DHistech P1000 at $82.44 \times$ magnification. 370

Structured pathological data originating from the analysis of the primary tumor 371 and lymph node sections was harmonized and compiled in tabular format. It includes 372 comprehensive information such as the cancer site, staging, grading, and histologic 373 type. The clinical data includes each patient's age, sex, and smoking status. It fur-374 ther contains information and timestamps of events such as treatments, recurrence, 375 progress, metastasis, or death. The data was collected from the hospital information 376 system and by screening various documents such as general and radiotherapy records. 377 Blood test results of the corresponding patients in a range of 14 days around local 378 surgery were retrieved from the hospital's archive. Each measurement was accompa-379 nied by the parameter's name, group, unit, and LOINC code (Logical Observation 380 Identifiers Names and Codes) [37]. 381

Surgery reports were collected by filtering the hospital's database by patient identifiers and time range. Reports of patients diagnosed in 2006 were not available, as reports were not entered into the database until 2007. The surgery reports follow a template that includes the medical history and report in the document's body and metadata in the header. All documents were compiled into a .pdf file.

³⁸⁷ Data preprocessing

The data was anonymized by assigning a unique, consecutive ID ("001" to "763") randomly to each patient. Our data is patient-centered. This means that each WSI, each core in a TMA, each surgery report, and each entry in the structured data is mapped to a single patient ID. The preprocessing steps for each data modality are described in the following.

TMAs and WSIs were converted from the manufacturer's file format (.mrxs) to the pyramidical Aperio file format (.svs). An Aperio SVS file contains a macro image and a label image. The label image in particular contains potentially identifying information. Therefore, we anonymized the files by removing the label images, i.e., by replacing the image with zeros. To allow the mapping of each TMA core to the corresponding patient, we created TMA maps in .csv format (comma-separated values) that can be imported into QuPath.

We identified the most important clinical and pathological features and ensured 400 that these were complete for all patients. We performed data cleaning to remove incon-401 sistent or redundant data. For patients with more than one entry in the clinical table, 402 we kept the entry with the earlier diagnosis date. Each following entry was discarded 403 because it reported a recurrence of the disease rather than the initial diagnosis. We 404 de-identified the clinical and pathological data by removing all names and dates. The 405 vear of the initial diagnosis was retained, but its date was removed. For anonymiza-406 tion purposes, all dates of events were replaced by the number of days since the initial 407 diagnosis. This way, the timeline from the diagnosis to the end of treatment could 408 still be reconstructed. We corrected spelling errors, summarized and harmonized table 409 entries, and assigned self-explanatory labels. The tables were finally converted into 410 Javascript-Object Notation (JSON). Descriptions of all fields in the JSON files with 411 their data types and possible values were summarized in data dictionaries, shown in 412 Supplementary Tables S1, S2, and S3. 413

The results of blood tests were available as structured, tabular data. We first 414 filtered the data to select values that were measured at specified units, excluding 415 intensive care units. For each patient, we chose a single pre-operative measurement 416 of each parameter. To this end, we selected the latest available measurement before 417 the surgery date because relevant blood tests are usually performed one to three days 418 before. If no pre-operative value was available, the value from the surgery day itself 419 was selected. The number of available measurements for these time points is shown 420 in Supplementary Fig. S12. The complete blood count, coagulation parameters, elec-421 trolytes, and renal function parameters were routinely assessed. Additional parameters 422 were calcium, magnesium, glomerular filtration rate, and glucose. Although it was only 423 available for 94 patients, we included C-reactive protein (CRP) since elevated CRP 424 levels are associated with poor prognosis in patients with head and neck cancer [38]. 425 The blood dataset was converted to JSON format. 426

The surgery reports were first converted from .pdf to .txt format. Each document had a header containing the operating clinicians, treatment date, the patient's name, and identifiers such as the admission number. The header additionally contained OPS codes and ICD codes. We used regular expressions in Python to search for keywords and obtain relevant data. This way, we extracted ICD codes, OPS codes, and the

medical history along with the surgery report itself. We selected reports from the first 432 treatment date, i.e. from the local surgery, and discarded all others. Most patient 433 names had already been masked when they had been entered into the system. How-434 ever, many texts contained names of operating clinicians. Therefore, we used regular 435 expressions to substitute any names following medical or academic titles. Addition-436 ally, we performed a search using regular expressions and lists of all names of patients 437 and clinicians. Finally, the reports and medical histories were screened manually for 438 any remaining identifying information. Patient names, clinician names, locations, and 439 dates were replaced by placeholders. The number of replaced terms is shown in Sup-440 plementary Table 4. The documents were saved to plain text (.txt) files. Additionally, 441 we translated all surgery reports, and medical histories from German to English using 442 the DeepL API [39]. For translating short descriptions to English, we used ChatGPT 443 (GPT-3.5) [40]. For convenience, HANCOCK contains the German original and the 444 translated version of the texts. Supplementary Fig. S3 shows word clouds of the most 445 common terms in the translated documents. 446

447 Annotation of primary tumor sections

For training AI models on WSIs using supervised learning, the annotation or seg-118 mentation of present tumor regions is usually required [22]. WSIs often contain large 449 areas of tissue that might be irrelevant or even misleading for the corresponding 450 task. We sparsely annotated representative tumor areas in the primary tumor sections 451 using QuPath. To this end, we manually selected one or several regions of interest 452 representing the tumor's histology while avoiding areas that contain artifacts, white 453 background, or healthy tissue such as muscular or glandular tissue. This approach is 454 based on the protocol for the analysis of deep texture representations [41]. An exhaus-455 tive annotation of all present tumor regions or distinct tissue types was not possible 456 due to time constraints. We provide the resulting polygon annotations in ".geojson" 457 format to enable effortless extraction of tumor tiles for future works. 458

459 Multimodal patient vectors

We created multimodal patient vectors for two purposes. First, the vectors were used
to determine a dataset split for training and testing. Second, they were used to train
models to predict outcomes or treatment choices. To this end, we created embeddings
that condensed data from each modality and concatenated them to a single vector
per patient.

We encoded the clinical and pathological features using different techniques based on their type. Binary encoding was applied for features such as lymphatic, vascular, or perineural invasion, the patient's sex, or the presence of carcinoma in situ. The pT stage and pN stage were considered ordinal features and transformed into consecutive labels. Categorical features such as primary site or histologic type were assigned labels and were later one-hot encoded. For integrating laboratory parameters, we used the raw values of the hematology group, i.e. the complete blood count.

The ICD codes, extracted from surgery reports, provide a more detailed classification of the disease than the available structured data does. The sequence of ICD

474 codes for each patient was considered a sentence and converted to vectors using a bag-

475 of-words model, inspired by the bag-of-disease-codes approach by Placido et al. [42].

⁴⁷⁶ To this end, the first four characters of each ICD code were used. Codes covered by

⁴⁷⁷ less than three patients were discarded.

The structured pathological data did not contain any information about the 478 immune response of each patient. To include this information, we performed a quan-479 titative analysis of TMAs using the open-source software QuPath (version 0.4.3) [43]. 480 The density of T lymphocytes has been shown to be a prognostic marker [44, 45]. 481 Inspired by the Immunoscore [24, 46], we computed the density of CD3- and CD8-482 positive cells in the tumor center and invasion front per tumor area. To this end, we 483 used QuPath to de-array the TMAs and match the tissue cores with patient IDs. Next, 484 tissue detection was performed using thresholding. Strong artifacts were manually 485 removed from the detected regions. Using QuPath's positive cell detection feature, we 486 obtained the positive cell count per mm² tumor area. Supplementary Fig. S13A shows 487 exemplary TMA cores with detected positive cells and Supplementary Fig. S13B the 488 respective cell densities. The distribution of the densities is shown in Supplementary 489 Fig. S13C. 490

The single-modality vectors for each patient were finally concatenated to a multimodal vector with a length of 103. We used UMAP to visualize the multimodal patient vectors in 2D. Beforehand, one-hot encoding was performed for categorical features, missing values were imputed, and z-score normalization was applied to ordinal and numeric features, i.e. the values were centered around the mean with unit variance. The axes were normalized to the range between zero and one.

⁴⁹⁷ Dataset split using a genetic algorithm

We aimed to provide a training dataset and a test dataset that is suitable to test 498 any AI algorithm for its generalizability. We aimed for our test dataset to fulfill the 499 following criteria proposed by Wagner et al. [18]: First, the data should be split at 500 a patient level. Second, both datasets should follow a similar distribution of target 501 classes, in this case, the recurrence and survival status. We created two distinct dataset 502 splits, each into 80% training and 20% test data. The first split should follow the 503 distribution of the training dataset concerning relevant characteristics, by including 504 information from different modalities. The second should be out of distribution and 505 contain outlier cases. To create both splits, we used evolutionary optimization [47]. 506

We implemented a genetic algorithm, where each individual represented a possible 507 split by a vector of zeros (patients assigned to training) and ones (patients assigned 508 to test). The objective of the genetic algorithm was to maximize the fitness of an 509 individual, i.e. of a split with N test points. Before computing the fitness of each 510 split, missing values were imputed and categorical features were subsequently one-hot 511 encoded. A penalty was subtracted from the fitness to achieve a class-balanced split. 512 This penalty was defined as the sum of differences between each class distribution d =513 $\frac{N_{positive}}{N}$ overall and in the current test dataset. Considering recurrence and survival 514 status as target classes, the number of classes was C = 2 in our case. The penalty for 515 C classes was weighted by a weight α . A similar approach was introduced by Florez-516 Revuelta who used a genetic algorithm to split multi-label data while maximizing the 517

similarity between class distributions [48]. We calculated the fitness of an individual
 as follows:

For the in-distribution split, the fitness of an individual was defined as the sum of cosine distances from each test point x_i to its nearest neighboring test point $x_{i,nn}$:

$$\text{fitness}_{in} = \sum_{i=1}^{N} \left(1 - \frac{\vec{x_i} \cdot \vec{x}_{i,nn}}{\|\vec{x_i}\| \|\vec{x}_{i,nn}\|} \right) - \alpha \sum_{k=1}^{C} |d_k - d_{k,all}|$$

For the out-of-distribution split, we calculated the sum of cosine distances between all pairs of test points x:

$$\text{fitness}_{out} = \sum_{i=1}^{N-1} \sum_{j=i+1}^{N} \left(1 - \frac{\vec{x_i} \cdot \vec{x_j}}{\|\vec{x_i}\| \|\vec{x_j}\|} \right) - \alpha \sum_{k=1}^{C} |d_k - d_{k,all}|$$

The population size was set to 10,000 and the genetic algorithm was terminated after 50 iterations with no further improvement. The population was iteratively updated using parent selection (tournament selection with elitism) and one-point crossover with inversion mutation until convergence. The genetic algorithm was only applied to patients with complete patient vectors. However, for some patients not all required modalities were available. These were subsequently assigned to the training dataset. The final splits were summarized as a list of patient IDs in JSON format.

⁵³¹ Outcome prediction for distinct dataset splits

For training Machine Learning models to predict recurrence or survival, three different 532 data splits were used. The first split defined "in distribution" cases as test data, 533 the second split defined "out of distribution" data as test data, and the third split 534 defined cases with oropharyngeal cancer as test data (see Figure 2D. For survival 535 prediction (see Figure 2E), cases with non-tumor-specific death were excluded. All 536 other cases, including those with unknown causes of death, were considered. The class 537 labels correspond to the survival status, i.e. "living" and "deceased". Binary class 538 labels were also defined for recurrence prediction (see Figure 2E). The classes were 539 defined as (i) patients who had no recurrence and survived at least three years and 540 (ii) patients who had a recurrence within three years. 541

As recommended by Huang et al., we applied an early fusion approach as an initial strategy, i.e. we created the multimodal patient vectors and trained a single model [19]. We used three different train-test splits of the dataset, namely the in-distribution and out-of-distribution datasets created using the genetic algorithm. Another split was created by assigning all laryngeal carcinomas to the test dataset. We used the Synthetic Majority Oversampling Technique (SMOTE) to handle class imbalance [49]. One classifier was trained and tested for each of the three splits (see Figure 2D).

549 Treatment prediction using Machine Learning

To explore the ability of an AI model to suggest whether adjuvant therapy is needed or not, we split the dataset in the following way. Patients who had no adjuvant therapy but were deceased or had a recurrence, metastasis, or progress were assigned to the

> ⁵⁵³ hold-out test dataset. All remaining cases were assigned to the training dataset, as ⁵⁵⁴ shown in Figure 3A. We chose this setting to explore if an AI model could potentially ⁵⁵⁵ identify patients who did not receive but would have needed adjuvant therapy. In ⁵⁶⁶ identifying deceased patients, we considered the overall survival as the cause of death ⁵⁵⁷ was not available for all cases. The class labels were defined as "no adjuvant therapy ⁵⁵⁸ used" and "adjuvant therapy used".

> We used the single-modality vectors (clinical, pathological, blood, ICD codes, TMA 559 cell densities) individually and their combination (multimodal patient vectors) to 560 train Random Forest classifiers. For both single-modal and multimodal data, we used 561 10-fold cross-validation and reported the average ROC curve along with the AUC 562 score. To handle the class imbalance problem, we applied SMOTE [49]. To avoid data 563 leakage, we ensured that missing value imputation and normalization were performed 564 in each iteration using statistics of the current training folds. To investigate the most 565 important features, we computed SHAP values and visualized them for the ten most 566 relevant features in a summary plot [23]. Finally, a classifier was trained on the full 567 training dataset of multimodal patient vectors and the predictions for the test dataset 568 were obtained. The training was performed for five iterations and the resulting ROC 569 curves and AUC scores were averaged. 570

571 Treatment prediction using Deep Neural Networks

Aiming to integrate histologic features into a model for treatment prediction, we used 572 the same dataset split as before (see 3A) and trained a Convolutional Neural Network. 573 To this end, we extracted features from TMAs stained using all eight available markers. 574 Each slide image contains tissue cores of several patients. To map these cores to patient 575 IDs, we de-arrayed the TMAs using QuPath and imported the TMA maps. Next, we 576 extracted a single tile from the center of each TMA core. As for most patients, two 577 cores and eight markers were available, resulting in 16 tiles per patient. Every tile was 578 fed to a feature extractor to obtain an embedding vector of length 256. To this end, 579 we used the feature extractor implemented by Komura et al. [27] which computes a 580 gram-matrix of feature maps obtained from convolutional layers in the network and 581 converts it to a one-dimensional embedding. We used a VGG16 as a feature extractor 582 pre-trained on ImageNet and obtained features from the layer "block3_conv3" [25, 26]. 583 Next, we stacked the extracted image features and multimodal patient vectors to 584 obtain a 2D embedding for each patient. Min-max scaling was applied to the image 585 features using the minimum and maximum value computed from all image features 586 in the training dataset. We trained a custom CNN on the image-like embeddings 587 and performed a grid search to tune its hyperparameters. The approach of encod-588

⁵⁸⁹ ing and stacking multimodal features into a single source suitable for training CNNs
⁵⁹⁰ was inspired by Nawaz et al. who fused image and text embeddings to improve
⁵⁹¹ classification performance [50].

We applied 10-fold cross-validation and reported ROC curves. A final model was trained on the full dataset and test predictions were obtained. To visually explain predictions, SHAP image plots were created for test samples [51]. As background samples for the SHAP algorithm, 100 random training samples were used.

596 Data analysis

Overall survival curves were estimated using the Kaplan-Meier method [52]. The anal-597 ysis considered the time between the initial diagnosis and death or the end of follow-up. 598 Patients who were alive at the end of the follow-up were censored. We computed 599 overall survival curves for all patients and for patients grouped by different character-600 istics, see Supplementary Fig. S6. For estimating the recurrence-free survival (see Fig. 601 3E), any occurrence of metastasis, progress, recurrence, or death was considered as an 602 event and the duration was defined as the time between the first treatment (surgery) 603 and the event. 604

The clinical data includes various events, such as treatments, progress of the disease, diagnosis of metastases, recurrence, and death or end of follow-up. We visualized the timelines of these events, see Supplementary Fig. S5.

508 Statistics and Evaluation

The performance of classifiers was reported using ROC curves and corresponding AUC scores. To compute ROC curves and AUC scores, ML models were either trained and evaluated five times (see Figure 2E) or trained using 10-fold cross-validation (see Figures 3B and 4D). The ROC curves and AUC scores were then averaged over the iterations or the ten folds, respectively.

To evaluate the results of classifiers trained to predict adjuvant treatment, Kaplan-614 Meier curves were estimated and compared. To this end, we split the test cases into 615 two groups based on the predicted classes. The first group contained cases where no 616 adjuvant treatment was predicted (probability for adjuvant therapy recommendation 617 below or equal to 0.5) and the second group contained cases where adjuvant treatment 618 was predicted (probability above 0.5). Kaplan-Meier curves were estimated separately 619 for the two groups. We used a log-rank test to compare survival curves and reported 620 whether the p-value was below the significance level of 0.05 (*), 0.001 (**), or 0.0001621 (***). 622

We applied the Wilcoxon-Mann-Whitney test to compare the distribution of CD3positive and CD8-positive cell density of patients grouped by recurrence and survival status, as shown in Supplementary Fig. S8.

626 Data availability

The HANCOCK dataset is publicly available at https://hancock.research.fau.eu/. An overview of the dataset, including the number and format of files, is shown in Supplementary Fig. S14.

630 Code availability

⁶³¹ Code for data exploration, processing histologic images, feature extraction, generating ⁶³² data splits, outcome prediction, and adjuvant treatment prediction is available at ⁶³³ https://github.com/ankilab/HANCOCK_MultimodalDataset.

Supplementary information. The supplement contains the SupplementaryFigures S1-S14 and the Supplementary Tables S1-S4.

Acknowledgments. This work was funded in part by the Federal Ministry of
 Education and Research (BMBF) to AOG and ME (01KD2211B) and to AMK
 (01KD2211A). We thank Mohammadhamed Mirbagheri for his excellent technical
 assistance.

References

- Sung, H., Ferlay, J., Siegel, R.L., Laversanne, M., Soerjomataram, I., Jemal, A., Bray, F.: Global cancer statistics 2020: Globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: a cancer journal for clinicians **71**(3), 209–249 (2021)
- [2] Johnson, D.E., Burtness, B., Leemans, C.R., Lui, V.W.Y., Bauman, J.E., Grandis, J.R.: Head and neck squamous cell carcinoma. Nature reviews Disease primers 6(1), 92 (2020)
- [3] Budach, V., Tinhofer, I.: Novel prognostic clinical factors and biomarkers for outcome prediction in head and neck cancer: a systematic review. The Lancet Oncology 20(6), 313–326 (2019)
- [4] Gatta, G., Botta, L., Sánchez, M.J., Anderson, L.A., Pierannunzio, D., Licitra, L., Hackl, M., Zielonke, N., Oberaigner, W., Van Eycken, E., *et al.*: Prognoses and improvement for head and neck cancers diagnosed in europe in early 2000s: The eurocare-5 population-based study. European journal of cancer 51(15), 2130–2143 (2015)
- [5] Chow, L.Q.: Head and neck cancer. New England Journal of Medicine 382(1), 60-72 (2020)
- [6] Cramer, J.D., Burtness, B., Le, Q.T., Ferris, R.L.: The changing therapeutic landscape of head and neck cancer. Nature reviews Clinical oncology 16(11), 669–683 (2019)
- [7] Leemans, C.R., Snijders, P.J., Brakenhoff, R.H.: The molecular landscape of head and neck cancer. Nature Reviews Cancer 18(5), 269–282 (2018)
- [8] Wang, Z., Jensen, M.A., Zenklusen, J.C.: A practical guide to the cancer genome atlas (tcga). Statistical Genomics: Methods and Protocols, 111–141 (2016)
- [9] Ang, K.K., Harris, J., Wheeler, R., Weber, R., Rosenthal, D.I., Nguyen-Tân, P.F., Westra, W.H., Chung, C.H., Jordan, R.C., Lu, C., *et al.*: Human papillomavirus and survival of patients with oropharyngeal cancer. New England Journal of Medicine **363**(1), 24–35 (2010)
- [10] Lechner, M., Liu, J., Masterson, L., Fenton, T.R.: Hpv-associated oropharyngeal cancer: Epidemiology, molecular biology and clinical management. Nature reviews Clinical oncology 19(5), 306–327 (2022)

- [11] Burtness, B., Harrington, K.J., Greil, R., Soulières, D., Tahara, M., Castro, G., Psyrri, A., Basté, N., Neupane, P., Bratland, Å., et al.: Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (keynote-048): a randomised, open-label, phase 3 study. The Lancet **394**(10212), 1915–1928 (2019)
- [12] Network, C.G.A., et al.: Comprehensive genomic characterization of head and neck squamous cell carcinomas. Nature 517(7536), 576 (2015)
- [13] The Clinical Proteomic Tumor Analysis Consortium Head and Neck Squamous Cell Carcinoma Collection (CPTAC-HNSCC) (Version 16) [Data set]. The Cancer Imaging Archive (2018). https://doi.org/10.7937/K9/TCIA.2018.UW45NH81
- [14] Grossberg, A.J., Mohamed, A.S., Elhalawani, H., Bennett, W.C., Smith, K.E., Nolan, T.S., Williams, B., Chamchod, S., Heukelom, J., Kantor, M.E., *et al.*: Imaging and clinical data archive for head and neck squamous cell carcinoma patients treated with radiotherapy. Scientific data 5(1), 1–10 (2018)
- [15] Elhalawani, H., Mohamed, A.S., White, A.L., Zafereo, J., Wong, A.J., Berends, J.E., AboHashem, S., Williams, B., Aymard, J.M., Kanwar, A., et al.: Matched computed tomography segmentation and demographic data for oropharyngeal cancer radiomics challenges. Scientific data 4, 170077 (2017)
- [16] NCI Cancer Institute Genomic Data Commons Data Portal. https://portal.gdc. cancer.gov Accessed 2024-04-30
- [17] ICD-10-GM Version 2024, Systematisches Verzeichnis, Internationale Statistische Klassifikation der Krankheiten und Verwandter Gesundheitsprobleme, 10. Revision, German Modification, Stand 15. September 2023, Köln (2024). Bundesinstitut für Arzneimittel und Medizinprodukte (BfArM) im Auftrag des Bundesministeriums für Gesundheit (BMG) unter Beteiligung der Arbeitsgruppe ICD des Kuratoriums für Fragen der Klassifikation im Gesundheitswesen (KKG). https://www.bfarm.de/DE/Kodiersysteme/Services/Downloads/_node. html#anker-icd-10-gm-downloads (visited 2024-04-18)
- [18] Wagner, S.J., Matek, C., Shetab Boushehri, S., Boxberg, M., Lamm, L., Sadafi, A., Waibel, D.J., Marr, C., Peng, T.: Make deep learning algorithms in computational pathology more reproducible and reusable. Nature Medicine 28(9), 1744–1746 (2022)
- [19] Huang, S.-C., Pareek, A., Seyyedi, S., Banerjee, I., Lungren, M.P.: Fusion of medical imaging and electronic health records using deep learning: a systematic review and implementation guidelines. NPJ digital medicine 3(1), 136 (2020)
- [20] Soenksen, L.R., Ma, Y., Zeng, C., Boussioux, L., Villalobos Carballo, K., Na, L., Wiberg, H.M., Li, M.L., Fuentes, I., Bertsimas, D.: Integrated multimodal

artificial intelligence framework for healthcare applications. NPJ digital medicine 5(1), 149 (2022)

- [21] Chen, R.J., Lu, M.Y., Wang, J., Williamson, D.F., Rodig, S.J., Lindeman, N.I., Mahmood, F.: Pathomic fusion: an integrated framework for fusing histopathology and genomic features for cancer diagnosis and prognosis. IEEE Transactions on Medical Imaging 41(4), 757–770 (2020)
- [22] Laak, J., Litjens, G., Ciompi, F.: Deep learning in histopathology: the path to the clinic. Nature medicine 27(5), 775–784 (2021)
- [23] Lundberg, S.M., Erion, G., Chen, H., DeGrave, A., Prutkin, J.M., Nair, B., Katz, R., Himmelfarb, J., Bansal, N., Lee, S.-I.: From local explanations to global understanding with explainable ai for trees. Nature Machine Intelligence 2(1), 2522–5839 (2020)
- [24] Foersch, S., Glasner, C., Woerl, A.-C., Eckstein, M., Wagner, D.-C., Schulz, S., Kellers, F., Fernandez, A., Tserea, K., Kloth, M., *et al.*: Multistain deep learning for prediction of prognosis and therapy response in colorectal cancer. Nature medicine 29(2), 430–439 (2023)
- [25] Simonyan, K., Zisserman, A.: Very deep convolutional networks for large-scale image recognition. arXiv preprint arXiv:1409.1556 (2014)
- [26] Deng, J., Dong, W., Socher, R., Li, L.-J., Li, K., Fei-Fei, L.: Imagenet: A largescale hierarchical image database. In: 2009 IEEE Conference on Computer Vision and Pattern Recognition, pp. 248–255 (2009). Ieee
- [27] Komura, D., Kawabe, A., Fukuta, K., Sano, K., Umezaki, T., Koda, H., Suzuki, R., Tominaga, K., Ochi, M., Konishi, H., et al.: Universal encoding of pan-cancer histology by deep texture representations. Cell Reports 38(9) (2022)
- [28] Yao, J., Zhu, X., Huang, J.: Deep multi-instance learning for survival prediction from whole slide images. In: Medical Image Computing and Computer Assisted Intervention–MICCAI 2019: 22nd International Conference, Shenzhen, China, October 13–17, 2019, Proceedings, Part I 22, pp. 496–504 (2019). Springer
- [29] Yao, J., Zhu, X., Jonnagaddala, J., Hawkins, N., Huang, J.: Whole slide images based cancer survival prediction using attention guided deep multiple instance learning networks. Medical Image Analysis 65, 101789 (2020)
- [30] Lu, M.Y., Williamson, D.F., Chen, T.Y., Chen, R.J., Barbieri, M., Mahmood, F.: Data-efficient and weakly supervised computational pathology on whole-slide images. Nature Biomedical Engineering 5(6), 555–570 (2021)
- [31] Geessink, O.G., Baidoshvili, A., Klaase, J.M., Ehteshami Bejnordi, B., Litjens, G.J., Pelt, G.W., Mesker, W.E., Nagtegaal, I.D., Ciompi, F., Laak, J.A.:

Computer aided quantification of intratumoral stroma yields an independent prognosticator in rectal cancer. Cellular oncology **42**, 331–341 (2019)

- [32] AbdulJabbar, K., Raza, S.E.A., Rosenthal, R., Jamal-Hanjani, M., Veeriah, S., Akarca, A., Lund, T., Moore, D.A., Salgado, R., Al Bakir, M., *et al.*: Geospatial immune variability illuminates differential evolution of lung adenocarcinoma. Nature medicine **26**(7), 1054–1062 (2020)
- [33] Schneider, L., Laiouar-Pedari, S., Kuntz, S., Krieghoff-Henning, E., Hekler, A., Kather, J.N., Gaiser, T., Froehling, S., Brinker, T.J.: Integration of deep learningbased image analysis and genomic data in cancer pathology: A systematic review. European journal of cancer 160, 80–91 (2022)
- [34] Kaul, R., Ossai, C., Forkan, A.R.M., Jayaraman, P.P., Zelcer, J., Vaughan, S., Wickramasinghe, N.: The role of ai for developing digital twins in healthcare: The case of cancer care. Wiley Interdisciplinary Reviews: Data Mining and Knowledge Discovery 13(1), 1480 (2023)
- [35] Zandberg, D.P., Strome, S.E.: The role of the pd-l1: Pd-1 pathway in squamous cell carcinoma of the head and neck. Oral oncology **50**(7), 627–632 (2014)
- [36] Cornel, A.M., Mimpen, I.L., Nierkens, S.: Mhc class i downregulation in cancer: underlying mechanisms and potential targets for cancer immunotherapy. Cancers 12(7), 1760 (2020)
- [37] Forrey, A.W., Mcdonald, C.J., DeMoor, G., Huff, S.M., Leavelle, D., Leland, D., Fiers, T., Charles, L., Griffin, B., Stalling, F., *et al.*: Logical observation identifier names and codes (loinc) database: a public use set of codes and names for electronic reporting of clinical laboratory test results. Clinical chemistry 42(1), 81–90 (1996)
- [38] Chen, Y., Cong, R., Ji, C., Ruan, W.: The prognostic role of c-reactive protein in patients with head and neck squamous cell carcinoma: A meta-analysis. Cancer medicine 9(24), 9541–9553 (2020)
- [39] DeepL: Translate with DeepL API. https://www.deepl.com/de/pro-api?cta= menu-pro-api Accessed 2024-02-16
- [40] OpenAI: ChatGPT (February 2024 version) [Large language model]. https:// chat.openai.com/
- [41] Herdiantoputri, R.R., Komura, D., Fujisaka, K., Ikeda, T., Ishikawa, S.: Deep texture representation analysis for histopathological images. STAR protocols 4(2), 102161 (2023)
- [42] Placido, D., Yuan, B., Hjaltelin, J.X., Zheng, C., Haue, A.D., Chmura, P.J., Yuan, C., Kim, J., Umeton, R., Antell, G., *et al.*: A deep learning algorithm to

predict risk of pancreatic cancer from disease trajectories. Nature medicine **29**(5), 1113–1122 (2023)

- [43] Bankhead, P., Loughrey, M.B., Fernández, J.A., Dombrowski, Y., McArt, D.G., Dunne, P.D., McQuaid, S., Gray, R.T., Murray, L.J., Coleman, H.G., *et al.*: Qupath: Open source software for digital pathology image analysis. Scientific reports 7(1), 1–7 (2017)
- [44] Hecht, M., Gostian, A.O., Eckstein, M., Rutzner, S., Grün, J., Illmer, T., Hautmann, M.G., Klautke, G., Laban, S., Brunner, T., et al.: Safety and efficacy of single cycle induction treatment with cisplatin/docetaxel/durvalumab/tremelimumab in locally advanced hnscc: first results of checkrad-cd8. Journal for immunotherapy of cancer 8(2) (2020)
- [45] Tumeh, P.C., Harview, C.L., Yearley, J.H., Shintaku, I.P., Taylor, E.J., Robert, L., Chmielowski, B., Spasic, M., Henry, G., Ciobanu, V., et al.: Pd-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 515(7528), 568–571 (2014)
- [46] Pagès, F., Mlecnik, B., Marliot, F., Bindea, G., Ou, F.-S., Bifulco, C., Lugli, A., Zlobec, I., Rau, T.T., Berger, M.D., *et al.*: International validation of the consensus immunoscore for the classification of colon cancer: a prognostic and accuracy study. The Lancet **391**(10135), 2128–2139 (2018)
- [47] Simon, D.: Evolutionary Optimization Algorithms. John Wiley & Sons, ??? (2013)
- [48] Florez-Revuelta, F.: Evosplit: An evolutionary approach to split a multi-label data set into disjoint subsets. Applied Sciences 11(6), 2823 (2021)
- [49] Chawla, N.V., Bowyer, K.W., Hall, L.O., Kegelmeyer, W.P.: Smote: synthetic minority over-sampling technique. Journal of artificial intelligence research 16, 321–357 (2002)
- [50] Nawaz, S., Calefati, A., Janjua, M.K., Anwaar, M.U., Gallo, I.: Learning fused representations for large-scale multimodal classification. IEEE Sensors Letters 3(1), 1–4 (2018)
- [51] Lundberg, S.M., Lee, S.-I.: A unified approach to interpreting model predictions. Advances in neural information processing systems **30** (2017)
- [52] Kaplan, E.L., Meier, P.: Nonparametric estimation from incomplete observations. Journal of the American statistical association 53(282), 457–481 (1958)